Recent Updates
Recently added Catalysts

Cognition CT1812 Alzheimer's: Phase 2 Readout 2027

In 2026, several critical phase 3 readouts could reshape the landscape of their respective indications. We list 11 Phase 2 and Phase 3 trials, with trial registry primary completion dates from December 2026 to July 2028. Understanding these clinical trial results can significantly influence investment decisions.

The full Phase 2 and Phase 3 readouts to watch

Registry primary completionTickerDrugIndicationPhasePoA
2027-04CGTXCT1812, Placebo (-7% run-up)Early Alzheimer's DiseasePHASE2n/a
2026 (company release)MNOVMN-166, placebo (+10.2% run-up)Amyotrophic Lateral SclerosisPHASE2n/a
Reported September 2026MNOVMN-001, MN-001 placebo (+10.2% run-up)Diabetes Mellitus, Type 2PHASE2n/a
Q1 2027 (company release)MLTXSonelokimabHidradenitis SuppurativaPHASE3n/a 🔒
Reported August 2026MLTXSonelokimab, PlaceboArthritis, PsoriaticPHASE3n/a 🔒
Reported November 2026CORTMiricorilant (Cohort A), Placebo (Cohort A), Miricorilant (Cohort B), Placebo (Cohort B)Nonalcoholic Steatohepatitis (NASH)PHASE2n/a 🔒
2026-12CORTrelacorilantCushing SyndromePHASE2n/a 🔒
2028-01-26REGNBNT116, CemiplimabAdvanced Non-Small Cell Lung CancerPHASE2n/a 🔒
2026-12-12 (company release, ASH data)GILDanitocabtagene-autoleucelMultiple MyelomaPHASE2n/a 🔒
2028-07GILDAnitocabtagene Autoleucel, Cyclophosphamide, Fludarabine, Pomalidomide, Bortezomib, Dexamethasone, Daratumumab, CarfilzomibMultiple MyelomaPHASE3n/a 🔒
First half of December 2026 (company)BIIBLitifilimab, PlaceboLupus Erythematosus, SystemicPHASE3n/a 🔒

Dates are trial registry primary completion dates, not company guidance.

CGTX's CT1812: A Phase 2 Readout for Early Alzheimer's Disease

The trial registry lists primary completion of the Phase 2 CT1812 study in Early Alzheimer's Disease in April 2027. This follows a -7% run-up, signaling possible market skepticism or profit-taking. CT1812 targets the toxic effects of amyloid-beta, a key factor in Alzheimer's pathology. Positive results could mean a significant upside for CGTX, but disappointing outcomes might worsen the current downward trend. We'll be watching insider activity and market sentiment closely as this trial nears completion.

MNOV's MN-166: Insights on Amyotrophic Lateral Sclerosis

MediciNova expects topline results from the COMBAT-ALS trial of MN-166 by the end of 2026, aimed at treating Amyotrophic Lateral Sclerosis (ALS), a condition lacking many treatment options. The stock has seen a 10.2% run-up, hinting at investor optimism. Known for its neuroprotective properties, MN-166 could offer a new treatment avenue. However, a failure could sharply drop MNOV's stock price. We'll examine the trial's efficacy and safety, crucial for this vulnerable patient group.

MNOV's MN-001: A Phase 2 Readout for Type 2 Diabetes

MNOV has since reported topline results from its Phase 2 MN-001 trial in Type 2 Diabetes (September 2026). The stock had a 10.2% run-up before the results. MN-001 aims to improve insulin sensitivity, crucial for diabetes management. The competitive diabetes therapy market makes these results pivotal. The results will shape MNOV's position in the diabetes market.

Gated Items: A Broader Look at Upcoming Phase 3 Readouts

Beyond the Phase 2 trials above, eight gated items round out the table. MLTX has since reported Week 52 results for Sonelokimab in Hidradenitis Suppurativa from the Phase 3 VELA program (June 2026). Effective treatments for this condition remain few. CORT has since reported results from the Phase 2b MONARCH trial of Miricorilant in Nonalcoholic Steatohepatitis (NASH), a growing concern with the rise of metabolic syndrome (November 2026). These trials could significantly influence company valuations. We'll assess the market impact of these results.

The Importance of Timing in Phase 3 Readouts

Timing is crucial for phase 3 readouts. BIIB expects topline data from the Phase 3 TOPAZ-1 and TOPAZ-2 studies of Litifilimab in Systemic Lupus Erythematosus in the first half of December 2026. Lupus treatments have historically struggled to show efficacy, making this data critical. The timing of these readouts often impacts stock performance, as investors react to both results and the market context. We'll watch market sentiment and any insider trading activity that might signal investor confidence or doubt.

Risk Factors Associated with Phase 3 Readouts

Investing around phase 3 readouts carries significant risk. GILD plans to present updated iMMagine-1 data for anitocabtagene autoleucel in Multiple Myeloma at ASH on December 12, 2026, and the trial registry lists primary completion of the Phase 3 study in July 2028. Success might boost stock prices, but negative results could severely impact investor confidence. The complexity of oncology trials raises the stakes. We will evaluate efficacy and safety data to gauge these candidates' long-term viability. Understanding these risks is essential for informed investment decisions.

The bottom line

Staying informed about these pivotal phase 3 readouts will be key to making sound investment decisions.

Frequently asked questions

What are phase 3 readouts?
Phase 3 readouts are results from late-stage clinical trials assessing a drug's efficacy and safety before regulatory approval.
Why are these readouts important for investors?
They provide critical insights into a drug's potential market success and can significantly influence stock prices.
How do run-up percentages affect investment decisions?
Run-up percentages indicate market sentiment; a positive run-up suggests optimism, while a negative run-up may signal caution.
What risks are associated with investing based on clinical trial results?
Primary risks include potential negative results, which can lead to stock price declines and impact investor confidence.